Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | STS | P08842 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | CCR8 | P51685 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29042870 | 0.93 | USP30 (0.55) | DRD4STSGPR119JAK2JAK1 | |
| SCHEMBL29042881 | 0.93 | USP30 (0.55) | DRD4STSGPR119JAK2JAK1 | |
| SCHEMBL2106890 | 0.93 | STS (0.57) | DRD4STSKDM4EPKMGPR119 | |
| SCHEMBL28779688 | 0.87 | USP30 (0.58) | DRD4STSGPR119JAK2JAK1 | |
| SCHEMBL29042862 | 0.86 | USP30 (0.57) | DRD4STSKDM4EPKMGPR119 | |
| SCHEMBL29042864 | 0.86 | USP30 (0.57) | DRD4STSKDM4EPKMGPR119 | |
| SCHEMBL29042868 | 0.86 | USP30 (0.57) | DRD4STSKDM4EPKMGPR119 | |
| SCHEMBL28779701 | 0.86 | USP30 (0.55) | DRD4STSGPR119JAK2JAK1 | |
| SCHEMBL616004 | 0.85 | STS (0.60) | DRD4STSKDM4EPKMGPR119 | |
| SCHEMBL3025644 | 0.84 | ALDH1A1 (0.51) | DRD4STSKDM4EPKMGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765053-B2 | Methods of treatment using selective 5-HT2A inverse agonists | ACADIA PHARMACEUTICALS INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170165273-A9 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | ANDERSSON CARL-MAGNUS A (DK) | 2017-06-15 | — | — | US | disclosed |
| US-20160237036-A1 | AZACYCLIC COMPOUNDS | ACADIA PHARM INC (US) | 2016-08-18 | — | — | US | disclosed |
| US-9296694-B2 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150259291-A1 | AZACYCLIC COMPOUNDS | ACADIA PHARMACEUTICALS INC. | 2015-09-17 | — | — | US | disclosed |
| US-20110301191-A1 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | ANDERSSON CARL-MAGNUS A (DK) | 2011-12-08 | — | — | US | disclosed |
| US-20090186921-A1 | AZACYCLIC COMPOUNDS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20080051429-A1 | USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS | ACADIA PHARMACEUTICALS INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2007124136-A1 | USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS | ACADIA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| EP-1787984-A2 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | Arcadia Pharmaceuticals Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060194778-A1 | Serotonin receptor antagonist; psychological disorders; side effect reduction | ACADIA PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
| US-20060194834-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
| US-20050014757-A1 | Azacyclic compounds | ANDERSSON CARL-MAGNUS A (DK) | 2005-01-20 | — | — | US | disclosed |
| US-6815458-B2 | NERVOUS SYSTEM DISORDERS | ACADIA PHARMACEUTICALS, INC | 2004-11-09 | — | — | US | disclosed |
| US-6756393-B2 | AMIDES AND UREAS N-SUBSTITUTED WITH PIPERIDINE OR NORTROPANE; SEROTONIN INVERSE AGONISTS OR ANTAGONISTS; ANTIPSYCHOTIC | ACADIA PHARMACEUTICALS, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030220316-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2003-11-27 | — | — | US | disclosed |
| CN-1443167-A | Azacyclo compounds for the treatment of 5-hydroxytryptamine related disorders | ACADIA PHARM INC (US) | 2003-09-17 | — | — | CN | disclosed |
| EP-1263729-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | Acadia Pharmaceuticals Inc. (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020004513-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2002-01-10 | — | — | US | disclosed |
| WO-2001066521-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARMACEUTICALS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259291-A1 | AZACYCLIC COMPOUNDS | HTR6, TPMT, HNMT | DRD4 423/4885STS 1077/4885KDM4E 2186/4885 |
| US-20110301191-A1 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | HTR2A, HTR5A, HTR3B | DRD4 396/4885STS 1327/4885KDM4E 4226/4885 |
| US-20060194834-A1 | Azacyclic compounds | HTR6, HTR5A, HNMT | DRD4 294/4885STS 1122/4885KDM4E 2716/4885 |
| US-20090186921-A1 | AZACYCLIC COMPOUNDS | HTR6, HTR5A, HNMT | DRD4 294/4885STS 1122/4885KDM4E 2716/4885 |
| US-20030220316-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | DRD4 423/4885STS 1077/4885KDM4E 2186/4885 |
| US-20020004513-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | DRD4 423/4885STS 1077/4885KDM4E 2186/4885 |
| US-20080051429-A1 | USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS | HTR4, HTR3B, HTR2A | DRD4 135/4885STS 3882/4885KDM4E 729/4885 |
| US-20050014757-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | DRD4 423/4885STS 1077/4885KDM4E 2186/4885 |
| US-20170165273-A9 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | HTR2A, HTR5A, HTR3B | DRD4 396/4885STS 1327/4885KDM4E 4226/4885 |
| US-20160237036-A1 | AZACYCLIC COMPOUNDS | HTR6, TPMT, HNMT | DRD4 423/4885STS 1077/4885KDM4E 2186/4885 |
| US-20060194778-A1 | Serotonin receptor antagonist; psychological disorders; side effect reduction | HTR2A, HTR1A, HTR1B | DRD4 72/4885STS 554/4885KDM4E 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.